Close
Scientific Research Context
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), developed to increase the stability and duration of endogenous growth hormone signaling. Research interest in CJC-1295 has focused on endocrine signaling dynamics, pulsatile growth hormone release, and insulin-like growth factor-1 (IGF-1) modulation in controlled research settings.
Foundational research can be reviewed via PubMed, including: Long-acting GHRH analogs and CJC-1295 and growth hormone secretion.
What Is CJC-1295?
At a molecular level, CJC-1295 is a modified GHRH analog designed to resist enzymatic degradation (specifically DPP-4 cleavage). This modification extends its biological half-life compared to native GHRH. It is studied in research and professional contexts for its ability to influence growth hormone release patterns through specific receptor-mediated signaling in the pituitary gland.
How CJC-1295 Works
CJC-1295 binds to growth hormone–releasing hormone receptors in the pituitary, stimulating endogenous growth hormone secretion. Research emphasizes its role in preserving physiological pulsatility rather than continuous hormone exposure.
In advanced metabolic and longevity research, CJC-1295 is frequently evaluated alongside other metabolic peptides to observe multi-pathway endocrine regulation. Because it operates upstream in the signaling cascade, it is highly synergistic with compounds that target complementary receptors.
CJC-1295 and Ipamorelin:
This is one of the most widely studied pairings in peptide research. While CJC-1295 (a GHRH analog) extends the duration of the growth hormone pulse, Ipamorelin (a Growth Hormone Secretagogue) amplifies the strength of the pulse while simultaneously inhibiting somatostatin. Together, they create a «pulse and sustain» effect, amplifying natural GH release without spiking cortisol or prolactin.
CJC-1295 and Tirzepatide:
In models evaluating severe metabolic syndrome, researchers pair GLP-1/GIP receptor agonists like Tirzepatide with GHRH analogs like CJC-1295. While Tirzepatide modulates nutrient intake, gastric emptying, and insulin pathways, CJC-1295 is introduced to preserve lean body mass and counteract the muscle degradation often associated with rapid, calorie-restricted weight loss.
CJC-1295 and AOD-9604:
When comprehensive tissue repair and body composition are the research targets, these two are often evaluated together. CJC-1295 drives systemic recovery, protein synthesis, and IGF-1 elevation, while the AOD-9604 fragment specifically targets the mobilization of lipid stores (lipolysis) without competing for the same receptor sites.
Research-Supported Areas of Study
In preclinical and clinical research models, CJC-1295 has been studied in contexts related to:
• Growth hormone and IGF-1 signaling dynamics
• Endocrine axis regulation research
• Metabolic and body composition studies
• Age-related hormonal signaling research
• Circadian hormone rhythm evaluation
Onset of Biological Activity and Research Timeframes
Research involving CJC-1295 evaluates hormonal signaling responses over defined observation periods rather than immediate outcomes. Changes in growth hormone and IGF-1 levels in research settings are typically assessed over days to weeks, depending on study design. Individual responses vary based on biological context.
Regulatory and COFEPRIS Context in Mexico
In Mexico, peptides such as CJC-1295 are subject to regulatory oversight depending on formulation and intended use. Professional peptide distribution emphasizes documentation, traceability, and alignment with applicable COFEPRIS requirements. Myosfit operates with COFEPRIS-registered laboratory sourcing and documented quality controls.
Frequently Asked Questions
Is CJC-1295 the same as growth hormone?
No. CJC-1295 stimulates endogenous growth hormone release rather than supplying growth hormone directly.
Is CJC-1295 available in pharmacies in Mexico?
CJC-1295 is not typically sold as an over-the-counter pharmacy medication.
How quickly does CJC-1295 work?
Research focuses on hormonal signaling changes evaluated over defined study periods rather than immediate effects.
Is CJC-1295 approved for medical treatment?
CJC-1295 is not approved as a medical treatment, and research findings do not constitute medical advice.
Selected Scientific References
Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295. PubMed https://pubmed.ncbi.nlm.nih.gov/17018654/
Thorner MO et al. Long-acting GHRH analogs. PubMed https://pubmed.ncbi.nlm.nih.gov/18601684/
Veldhuis JD et al. GH pulsatility research. PubMed https://pubmed.ncbi.nlm.nih.gov/18940916/
Hartman ML et al. Endocrine regulation of GH. PubMed https://pubmed.ncbi.nlm.nih.gov/7566747/
Explore CJC-1295 Options Professionally sourced CJC-1295 formulations with an emphasis on quality, documentation, and COFEPRIS-registered laboratory sourcing.
• What peptides really are and how they function inside the body
• The logic and structure behind high-performance MyosFit stacks
• Fat loss, muscle recovery, sleep, longevity, and skin optimization strategies
• How advanced stacks are engineered, not guessed
• What defines clinical-grade peptides,s and why most products fail that standard
The date has not been announced yet – join the early interest list to be notified first when registration opens.
